artigo original / original article - Scielo.br

$57,*225,*,1$/25,*,1$/$57,&/(

!21'!

(%0!4)4)3"6!##).%%&&)#!#9). 0!4)%.437)4(#(2/.)#,)6%2 $)3%!3%"9(%0!4)4)3#6)253

!NGELO!LVESDE-!44/3 %LIANA"UKSZTEJN'/-%3 #RISTIANE6ALLE4/6/ #LÉUDIO/SMAR0EREIRA!,%8!.$2%AND*OSÏ/SCARDOS2EIS2%-)²/

!"342!#4 "ACKGROUND #ONSIDERINGTHEIMMUNOSUPPRESSIONOFPATIENTSWITHCHRONICLIVERDISEASE THEIRRESPONSETOVACCINATIONISDISCUSSED INLITERATURE!IMS 4OEVALUATETHERESPONSEOFHEPATITIS"VACCINEINPATIENTSWITHCHRONICHEPATITIS#VIRUSINFECTION-ETHODS 4HISISA PROSPECTIVESTUDYINWHICHPATIENTSWITHCHRONICHEPATITIS#VIRUSINFECTIONYEARS MALES ANDHEALTHYADULTS YEARSMALES WEREEVALUATED#ONlRMATIONOFHEPATITIS#VIRUSWASOBTAINEDBYTHETECHNIQUEOFPOLYMERASECHAINREACTION 6IRALLOADWASDETERMINEDBYTHEBRANCHED$.!METHODINPATIENTS ANDGENOTYPEWASDETERMINEDBYSEQUENCINGINPATIENTS!LL PATIENTSANDHEALTHYADULTSRECEIVEDTHREEDOSESOF%NGERIX"¤VACCINE)-AT ANDDAYS 3EROLOGICALRESPONSESTOTHEVACCINE WEREDIVIDEDINTOTHREECATEGORIESSEROPROTECTION WHENANTI ("SWASrM5)M,SEROCONVERSION WHENANTI ("SWAS M5)M, ANDNON REAGENT WHENANTI ("SWASM5)M,2ESULTS 4HERESPONSEOFHEPATITIS"VACCINEASDETERMINEDMONTHFOLLOWINGDOSE WASSEROPROTECTIONIN SEROCONVERSIONINANDNON REAGENTINAMONGPATIENTSAND RESPECTIVELYIN HEALTHYADULTS4HENUMBEROFNON REAGENTRESPONSESWASSIGNIlCANTLYHIGHERAMONGTHOSEPATIENTSWITHCHRONICLIVERDISEASE3IXTY lVE PATIENTSWITHCHRONICHEPATITISWERECOMPAREDTOCOMPENSATEDCIRRHOTICPATIENTSINCONCERNTOTHERESPONSETOVACCINE BUTNODIFFERENCE WASFOUND4HERESPONSETOVACCINEINPATIENTSWITHGENOTYPESORN WASBETTERTHANINTHOSEWITHGENOTYPEN 2ESPONSE WASNOTRELATEDTOSERUM(#6 2.!CONCENTRATION#ONCLUSION 4HENUMBEROFNON RESPONDERSWASHIGHERINPATIENTSWITHCHRONICHEPATITIS #VIRUSINFECTION IRRESPECTIVEOFHISTOLOGICALSTATUSANDVIRALLOAD)TISSUGGESTEDTHATSUCHPATIENTSSHOULDRECEIVEADOUBLEDOSEOFVACCINE PARTICULARLYTHEONESWITHGENOTYPE (%!$).'3 (EPATITIS"VACCINES,IVERDISEASES(EPACIVIRUS

).42/$5#4)/.

)NFECTION BY HEPATITIS " VIRUS ("6 IN A PATIENT WITH CHRONICLIVERDISEASE#,$ APPEARSTOACCELERATETHEPREEXISTING LIVERDAMAGE MAKINGITCRITICALTOPROTECTTHISPOPULATION AGAINSTTHEINFECTION )NDIVIDUALS WITH LIVER DISEASE SEEM TO SHOW A DECREASED RESPONSETO("6VACCINE BUTTHEEVALUATIONOFTHISPOPULATION OFPATIENTSISUSUALLYPERFORMEDINTRANSPLANTATIONCENTERS THUS INCLUDINGPATIENTSWITHMORESEVERELIVERDISEASES $ESPITETHEINCREASEDSEVERITYOF("6INFECTIONINPATIENTS WITHCHRONICLIVERDISEASE FEWSTUDIESHAVEBEENPERFORMEDIN PATIENTSWITHCOMPENSATEDDISEASE3PECIALATTENTIONMUSTBE GIVENTOPATIENTSWITHCHRONICLIVERDISEASECAUSEDBYHEPATITIS # VIRUS(#6 BECAUSEITACCOUNTSFOR OF THE CASES OF #,$ )NTHE.)(#ONSENSUS#ONFERENCE VACCINATION OFTHESEPATIENTSWASALREADYRECOMMENDED $UETOTHESCARCITYOFSTUDIESABOUTVACCINATIONFOR("6IN THISPOPULATION ASWELLASTHELACKOFSTUDIESASSESSING THERESPONSEINRELATIONTO(#6GENOTYPE WEFOUNDITVALUABLE TOAPPRECIATETHERESPONSETOTHEVACCINEINTHESEPATIENTS 4HISSTUDYWASDESIGNEDTOINVESTIGATETHEIMMUNOGENIC RESPONSEOFTHEVACCINEAGAINST("6INPATIENTSWITH#,$BY

HEPATITIS#VIRUS ASWELLASTHEROLEOFTHEHISTOLOGICALSTATUSOF THEDISEASEANDOF(#6GENOTYPEANDVIRALLOADINTHERESPONSE TOVACCINATION -!4%2)!,3!.$-%4(/$3 4HISSTUDYWASPERFORMEDATh)RMANDADE3ANTA#ASADE -ISERICØRDIAvOF0ORTO!LEGRE 23 "RAZIL WHEREANTI (#6 POSITIVEPATIENTSWEREPROSPECTIVELYSELECTEDFOREVALUATION OFTHERESPONSETOTHEVACCINEAGAINST("6FROM-AY TO-AY #ONlRMATIONOFANTI (#6STATUSWASOBTAINEDBYPOLYMERASE CHAINREACTION0#2 ANDPRESENCEOFCHRONICHEPATITISORCIRRHOSIS WASDETERMINEDTHROUGHCLINICAL LABORATORY ULTRASONOGRAPHIC ENDOSCOPIC ANDORANATOMOPATHOLOGICALSTANDARDS #IRRHOTICPATIENTSWERESORTEDUSINGTHEORIGINALCLASSIlCATION PROPOSEDBY#HILD 4URCOTTEANDMODIlEDBY0UGH !S A CONTROL GROUP HEALTHY VOLUNTEERS WORKING IN A PUBLICORGANIZATIONINTHESAMECITYWEREEVALUATED !LL PATIENTS HAD THEIR HEIGHT AND WEIGHT RECORDED AT THE BEGINNINGOFTHESTUDY ANDTHEIRBODYMASSINDEX"-) WAS CALCULATEDBYDIVIDINGPATIENTSWEIGHTKG BYTHESQUAREDHEIGHT

&ROMTHE$EPARTMENTOF'ASTROENTEROLOGYOFh&UNDAÎÍO&ACULDADE&EDERALDE#IÐNCIAS-ÏDICASvOF0ORTO!LEGRE&&&#-0! ANDh)RMANDADE3ANTA#ASADE-ISERICØRDIADE 0ORTO!LEGREv)3#-0! "RAZIL !DDRESSFORCORRESPONDENCE$R!NGELO!LVESDE-ATTOS 2UA!URÏLIO"ITENCOURT 0ORTO!LEGRE 23 "RAZIL%MAILHMB SANTACASATCHEBR

$UT*DVWURHQWHURO

Y±QR±MXOVHW

-ATTOS!! 'OMES%" 4OVO#6 !LEXANDRE#/0 2EMIÍO*/2(EPATITIS"VACCINEINPATIENTSWITHCHRONICLIVERDISEASEBYHEPATITIS#VIRUS

M 0ATIENTS WERE ALSO INQUIRED ABOUT THEIR DRINKING AND SMOKING BEHAVIOR!NINDIVIDUALWASCONSIDEREDASANALCOHOLICIFHESHEWOULD DRINKATLEASTGOFALCOHOLDAYMALES ANDGDAYFEMALES FORAT LEASTYEARS&ORSMOKERS THENUMBEROFCIGARETTESANDTHEDURATION OFTHEHABITWERERECORDED 4HE EXCLUSION CRITERIA WERE TRANSPLANTED PATIENTS OR THOSE ON WAITINGLISTS CHRONICRENALPATIENTS ()6 POSITIVEPATIENTS PATIENTSWITH NEOPLASIAS IMMUNOSUPPRESSEDPATIENTSINGENERALORTHOSESUBMITTED TO ANTIVIRAL THERAPY WITH INTERFERON FOR THE LAST MONTHS PREGNANT WOMEN AND PATIENTS UNDER OR OVER YEARS OF AGE )NDIVIDUALS ALREADYIMMUNIZEDAGAINSTHEPATITIS"PRESENCEOFANTI ("S ORTHOSE PREVIOUSLYEXPOSEDTO("6PRESENCEOFANTI ("C)G-OR)G' WERE ALSOEXCLUDED !LLANTI ("CANDANTI ("SNEGATIVEPATIENTSWHOWOULDNOTMATCHTHE EXCLUSIONCRITERIAANDWHOWOULDAGREEDTOPARTICIPATEINTHESTUDYHAD THEIRBLOODSAMPLEDFORIDENTIlCATIONOF(#6 2.!BY0#2ANDBLOOD BIOCHEMISTRYAMINOTRANSFERASES ALBUMIN PROTHROMBINTIME ALKALINE PHOSPHATASE ANDBILIRUBIN !DDITIONALSAMPLESWERESTOREDATnO# FORLATERVIRALQUANTIlCATIONBYTHEBRANCHED$.!METHODINWHICHTHE CUT OFFVALUEWAS-%QM, ANDGENOTYPEDETERMINATIONBYDIRECT SEQUENCINGOFPRODUCTSOBTAINEDFROMTHEAMPLIlCATIONBY0#2 !LLPATIENTSANDVOLUNTEERSRECEIVEDGRECOMBINANT$.!VACCINE %NGERIX"¤ INTRAMUSCULARADMINISTEREDATTHREEDIFFERENTTIMES ANDDAYS ATTHEDELTOIDREGION 1UANTITATIVE DETERMINATION OF ANTI ("S ANTIBODIES AND BLOOD BIOCHEMISTRY WERE PERFORMED ONE MONTH FOLLOWING DOSE IN BOTH GROUPSOFSTUDY 3EROPROTECTION30 WASCONSIDEREDIFANTI ("SLEVELSWEREEQUAL TOORABOVEM5)M, SEROCONVERSION3# IFANTI ("SLEVELSWERE BETWEENAND ANDNON REAGENTRESPONSE.2 IFANTI ("SLEVELS WEREBELOWM5)M,,ATERANEWRESPONSEVARIABLEWASCREATEDIN WHICHTHOSEWHOSHOWED30AND3#WOULDCONSIDEREDASRESPONDERS ANDTHEONESWHOWERE.2WOULDBECONSIDEREDASNON RESPONDERS ,OCALANDSYSTEMICSIDEEFFECTSRELATEDTOTHEVACCINEWEREDOCUMENTED UPTODAYSFOLLOWINGTHEADMINISTRATIONOFEACHDOSEOFVACCINE $ETECTIONOF("S!GWASPERFORMEDTHROUGHTHETHIRDGENERATION -ICROPARTICLE)MMUNOENZYMATIC4EST!X39-¤("S!GV THEPRESENCE OF ANTI ("C WAS DETECTED BY THE -ICROPARTICLE )MMUNOENZYMATIC 4EST!X39-¤#ORE¤ ANDANTI ("SWASQUANTITATIVELYDETECTEDBYTHE -ICROPARTICLE)MMUNOENZYMATIC4EST!X39-¤!USAB¤ ALLOFTHEM FROM!BBOTT$IAGNOSTICS$IVISION )LLINOIS 53! !NTI (#6WASDETECTEDBYTHE-ICROPARTICLE)MMUNOENZYMATIC 4EST-%)! !X39-¤(#6VERSION!BBOTT$IAGNOSTICS$IVISION )LLINOIS 53! &ORCONlRMATIONOFINFECTIONBYHEPATITIS#VIRUSTHE(#6!MPLICOR¤ TEST2OCHE$IAGNOSTIC3YSTEMS )NC "RACHBURG .* 53! WASUSED WHICHISADIRECTTESTWITH$.!PROBESUSINGTHETECHNIQUEOF$.! AMPLIlCATIONTHROUGH0#2&ORQUANTIlCATIONOFHEPATITIS#VIRUS THE METHODOFSECONDGENERATIONBRANCHED$.!B $.! SIGNALAMPLIlCATION 1UANTIPLEX¤(#62.!#HIRON$IAGNOSTICS#ALIFORNIA 53! WAS USED WHICHISASANDWICHHYBRIDIZATIONASSAYOFNUCLEICACIDSINSOLUBLE PHASEEMPLOYINGBRANCHED$.!MOLECULES4HEQUANTIlCATIONLIMITOF THETESTIS-%QM,OF(#62.!3AMPLESWITHVALUESBELOW THISTHRESHOLDARECONSIDEREDASNEGATIVE3AMPLESWITHVALUESABOVE -%QM,AREOUTOFTHESAFETYLIMITOFTHETESTSTANDARDCURVEAND MUSTBEDILUTEDSOTHATARELIABLEQUANTITATIVEVALUECANBEOBTAINED &OR(#6GENOTYPEDETERMINATIONITWASUSEDTHEMETHODOFAUTOMATIC

Y±QR±MXOVHW

SEQUENCING WHICHISPERFORMEDUSINGTHE0#2AMPLIlCATIONPRODUCT FROMREGIONNON ENCODED 4HE!")PRISMSEQUENCERWASUSED 0ERKIN %LMER!PPLIED"IOSYSTEMS &OSTER#ITY #ALIFORNIA 53! 4HISSTUDYWASSUBMITTEDTOANDAPPROVEDBYTHE%THICS#OMMITTEE OFh)RMANDADE3ANTA#ASADE-ISERICØRDIAvOF0ORTO!LEGRE 23 "RAZIL ANDALLPARTICIPANTSAUTHORIZEDTHEIRBLOODSAMPLECOLLECTION 0ATIENTANDCONTROLGROUPSWERECOMPAREDINRELATIONTOCONTINUOUS VARIABLESWITH3TUDENTSTTESTFORINDEPENDENTSAMPLESANDCHI SQUARETEST FORCATEGORICALVARIABLES&ORANTI ("SVARIABLESANDVIRALQUANTIlCATION BY BRANCHED $.! NON PARAMETRIC -ANN 7HITNEY TEST WAS USED 'RAPHICDEPICTIONOFTHESECOMPARISONSWASPERFORMEDTHROUGHBOX DIAGRAMS&ORTHEEVALUATIONOFTHEROLEOFAGEASACONFUSINGFACTORINTHE ASSOCIATIONBETWEENILLNESSANDVACCINALRESPONSE ALOGISTICREGRESSION WASPERFORMEDANDINCLUDEDGROUPANDAGEINAFORCEDENTRANCEMODEL 4HEOUTCOMEVARIABLEWASCONSIDEREDAShRESPONSEv3#30 &ORALL THESECOMPARISONLEVELSOFSIGNIlCANCEWAS 2%35,43 /FTHEPATIENTSPARTICIPATINGOFTHISSTUDY COMPLETEDTHETHREE DOSESOFVACCINATIONANDPERFORMEDTHEREQUIREDTESTS.INETEENPATIENTS DIDNOTRETURNAFTERTHESECONDDOSEOFVACCINE DIDNOTRETURNAFTER THETHIRDDOSE ANDINITIATEDTHERAPYWITHINTERFERONBEFORECOMPLETION OFTHEVACCINATIONSCHEDULE.OLOSSESOCCURREDINTHECONTROLGROUP 0ATIENTSMEANAGEWASYEARS YEARS WEREMALES AND WERECAUCASIAN ,IVERHISTOLOGYWASPERFORMEDINPATIENTS-INORHISTOLOGICAL ALTERATIONSWEREDETECTEDINPATIENTS HADCHRONICHEPATITISWITH LOWACTIVITYANDORPORTALlBROUSEXPANSION HADMODERATEACTIVITY ANDORSEPTALlBROSIS HADINTENSEACTIVITYANDORBRIDGEDlBROSIS ANDHADCIRRHOSIS )NREGARDTOTHEOTHERPATIENTS INTHEDIAGNOSISOFCHRONIC LIVERDISEASEWASESTABLISHEDWHENPATIENTSSHOWEDPOSITIVE0#2FOR (#6)NTHESECASESALANINEAMINOTRANSFERASE!,4 WASPERSISTENTLY NORMALORATLEVELSASHIGHASONEANDAHALFTIMESBELOWTHEUPPER VALUEOFNORMALITY REASONWHYBIOPSYWASNOTPERFORMED)NTHEOTHER lVE PATIENTS CIRRHOSIS DIAGNOSIS WAS BASED ON CLINICAL LABORATORY ULTRASONOGRAPHIC ANDENDOSCOPICSTANDARDS 4HEMEANAGEINTHECONTROLGROUPN WASYEARS YEARS WITH MALESAND CAUCASIAN /NEMONTHFOLLOWINGDOSEOFVACCINE OFPATIENTSSHOWED 30 SHOWED3# ANDWERE.2AND AMONGVOLUNTEERS THEVALUESWERE AND RESPECTIVELY&IGURE 4HE PERCENTAGEOF.2WASSIGNIlCANTLYHIGHERINPATIENTSWITHLIVERDISEASE 0 4HEODDSRATIOOBSERVEDFOR.2INPATIENTSINRELATIONTO VOLUNTEERSWASWITHCONlDENCEINTERVAL#) OFFROM TO !NTI ("SLEVELSRANGEDFROMTOM5)M,INPATIENTS WITH MEDIANEQUALTO ANDFROMTOM5)M,INVOLUNTEERS WITHMEDIAN&IGURE !NTI ("SLEVELSWERESIGNIlCANTLYHIGHER INVOLUNTEERS0 ! DIFFERENCE WAS FOUND BETWEEN THE MEAN AGE OF PATIENTS AND VOLUNTEERS0 !LOGISTICREGRESSIONWASPERFORMEDTOEVALUATE ITSROLEASACONFUSINGFACTORINTHECOMPARISONBETWEENPATIENTSAND VOLUNTEERSRESPONSETOVACCINE4HEMODELSHOWEDTHATAGEWASNOT SIGNIlCANTLYASSOCIATEDTORESPONSE0 WHENITWASCONTROLLED FORTHEPRESENCEORABSENCEOFTHE(#6INTHEINDIVIDUAL0

$UT*DVWURHQWHURO


3DWLHQWVZLWKYLUXV+&9Q

+HDOW\YROXQWHHUVQ

RELATIONTOVACCINALRESPONSEWHENINDIVIDUALSWEREEVALUATEDACCORDING TOTHEIRVIRALLOAD0 4HE SUBGROUPS OF NON RESPONDERS AND RESPONDERS 3# AND 30 WEREEVALUATEDINRELATIONTOAGE GENDER SMOKINGAND"-) ANDNO STATISTICALDIFFERENCEWASFOUNDBETWEENTHEM0 6ACCINATION DID NOT AFFECT THE LEVEL OF AMINOTRANSFERASES4HE MEANACTIVITIESOF!34AND!,4MEASUREDBEFOREVACCINATIONWERE 5, AND 5, RESPECTIVELY AND AFTER VACCINATION 5, 0 AND 5, 0 RESPECTIVELY /NLYFOURINDIVIDUALSOFALLINCLUDEDINTHESTUDYREPORTEDLIGHT PAINONTHEINJECTIONREGIONFOLLOWINGADMINISTRATIONOFDOSE WITHA DURATIONOFUPTO HOURS

$)3#533)/.

63

6&

15

&)'52% !NTI ("SRESULTSMONTHFOLLOWINGDOSEOFVACCINE

$QWL+%VPrVDSyVDDGRVHP8OP/

$QWL+%VPRQWKDIWHUGRVHP8OP/

3DWLHQWV

9ROXQWHHUV

*5283 &)'52% $ISTRIBUTIONOFANTI ("SVALUESBETWEENPATIENTSANDVOLUNTEERSMONTH FOLLOWINGDOSEOFVACCINE

)NRELATIONTOTHEOTHERVARIABLESGENDER "-) DRINKINGANDSMOKING THEREWASNODIFFERENCESBETWEENTHEGROUPS 4HERESPONSEOFTHEPATIENTSDIAGNOSEDWITHCHRONICHEPATITIS WASCOMPAREDTOTHATOFTHEPATIENTSWHOHADALREADYDEVELOPED CIRRHOSIS)NTHEFORMERGROUP 30WASFOUNDIN 3#IN AND.2ININCIRRHOTICPATIENTS THERESULTSWERE AND RESPECTIVELY0 /FTHEPATIENTSWHOWERESUBMITTEDTO(#6GENOTYPEDETERMINATION HADGENOTYPEANDHADGENOTYPESOR!MONGPATIENTSWITH GENOTYPE 30WASFOUNDIN 3#IN AND.2IN WHILEAMONGTHOSEWITHGENOTYPESOR PERCENTAGESWERE AND RESPECTIVELY4HEPERCENTAGEOF.2WASSIGNIlCANTLYHIGHER INPATIENTSWITHGENOTYPE0 6IRALQUANTIlCATIONWASPERFORMEDINPATIENTSANDSHOWEDAMEAN VALUEOF-%QM, VARYINGBETWEENAND-%QM,)N PATIENTSQUANTIlCATIONWASABOVE-%QM, WITH30DETECTED IN 3#IN AND.2IN4HEREWEREPATIENTSBELOW THIS CUT OFF VALUE WITH THE FOLLOWING RESPONSE DISTRIBUTION AND RESPECTIVELY.OSTATISTICALDIFFERENCEWASFOUNDIN

6ACCINESAGAINSTHEPATITISHAVETWOPURPOSESTOPREVENTMORBIDITYAND FORTUITOUSMORTALITYASSOCIATEDWITHACUTEVIRALINFECTION ANDTOREDUCE THEOCCURRENCEOFCHRONICLIVERDISEASEANDHEPATOCELLULARCARCINOMA ININFECTIONSTHATSHOWPROGRESS !TPRESENT ONLYVACCINESAGAINST HEPATITIS!AND"VIRUSESAREAVAILABLE !LTHOUGHHEPATITIS!DOESNOTPROGRESSTOTHECHRONICFORM CASES OFFULMINANTHEPATITISLEADINGTODEATHMAYOCCUR PARTICULARLYINAGED INDIVIDUALSORINPATIENTSWITH#,$ 4HUSTHE!DVIRSORY#OMMITTEE ON)MMUNIZATION0RACTICES!#)0 RECOMMENDSVACCINATIONAGAINST HEPATITIS!VIRUSINPEOPLESUFFERINGFROM#,$ 4HEIMMUNOGENICITYOFVACCINEAGAINST(!6ISFAIRLYSATISFACTORY INPATIENTSWITHCHRONICLIVERDISEASES )NTHISSTUDYWEHAVENOT EVALUATEDTHERESPONSETOVACCINEAGAINST(!6BECAUSEVIRTUALLYALL PATIENTSEVALUATEDALREADYHADIMMUNITYAGAINSTHEPATITIS!VIRUS WHICH ISINAGREEMENTTOTHElNDINGSTHAT IN"RAZIL MOSTADULTSHAVEALREADY BEENEXPOSEDTOTHISVIRUS )NTHE7ORLD(EALTH/RGANIZATIONRECOMMENDEDUNIVERSAL VACCINATIONFOR("6 "ESIDESALLTHEPOTENTIALBENElTSOFVACCINATION THIS WOULD AFFORD A CONSIDERABLE REDUCTION IN THE INCIDENCE OF HEPATOCELLULARCARCINOMA SINCE("6ISTHEWORLDLEADINGETIOLOGIC FACTORTOTHISNEOPLASIAANDISHIGHLYPREVALENTINDENSELYPOPULATED AREAS SUCHAS!FRICAORSOUTHEAST!SIA REGIONSWHICHACCOUNTFOR OFCASES (OWEVER SUCHRECOMMENDATIONISNOTFOLLOWEDBY ALLCOUNTRIES-OREOVER ITISBELIEVEDTHATNOTEVENRISKGROUPSARE VACCINATEDINASYSTEMATICWAY4HUS ALTHOUGHTHEVACCINEAGAINST HEPATITIS " HAS BEEN AVAILABLE FOR OVER TWO DECADES AND IS USED INRISKGROUPS ITISESTIMATEDTHATONLYOFTHISPOPULATIONIS VACCINATED 7/.'ETAL INVESTIGATEDIFPATIENTSWITHCHRONICLIVERDISEASE DEPENDENTONHEPATITIS#VIRUSWEREVACCINATEDAGAINSTHEPATITIS"AND FOUNDOUTTHATONLYOFTHEPATIENTSEVALUATEDHADPERFORMED PROPHYLAXIS4HEYCONCLUDEDTHEIRSTUDYBYEMPHASIZINGTHEROLEOF VACCINATION IN CARRIERS OF (#6 VIRUS SINCE THIS IS A POPULATION OF IMMUNOSUPPRESSEDPATIENTS 4HEIMPORTANCEOFVACCINATIONISSUPPORTEDBYTHEFACTTHATSUPERINFECTION WITH("6INPATIENTSWITH(#6NOTONLYWORSENSLIVERDISEASEBUTALSO FAVOURTHEPROGRESSTOCIRRHOSISANDHEPATOCARCINOMA !LTHOUGHANTI HEPATITIS"VACCINEHASSHOWNEXCELLENTRESULTSINHEALTHY INDIVIDUALS SEVERALAUTHORS HAVEREALIZEDTHATTHEPRESENCE OFADVANCEDCHRONICLIVERDISEASEHELPSTODECREASEIMMUNOGENICITYIN THEPRIMARYSERIESOFVACCINATION

$UT*DVWURHQWHURO

Y±QR±MXOVHW


)N THIS STUDY WE EVALUATED PATIENTS WITH COMPENSATED CHRONIC LIVERDISEASEANDFOUNDTHATSEROCONVERSIONRATESWERELOWERINTHESE PATIENTSANDTHATOFTHEMWERENON REAGENTSTOVACCINATION IN CONTRASTTOTHEOF.2AMONGHEALTHYVOLUNTEERS)MPORTANTLY IN THEPOPULATIONOFPATIENTSWITHCHRONICLIVERDISEASE WEFOUNDOUTNOT ONLYAHIGHERNUMBEROFPATIENTSWHODIDNOTRESPONDTOVACCINATION BUTALSOSIGNIlCANTLYLOWERANTI ("SLEVELS INDICATIVEOFASTATUSOF IMMUNOSUPPRESSION )NCONTRASTTOTHESElNDINGS SOMEAUTHORS NOTICEDTHAT PATIENTSWITHPOSITIVEANTI (#6ACHIEVEDANEXCELLENTPERCENTAGEOF SEROCONVERSIONAFTERTHECOMPLETECOURSEOFANTI HEPATITIS"VACCINATION (OWEVER SOMEOFTHESESTUDIESINVESTIGATEDALIMITEDNUMBEROFCASES ANDMOSTOFTHEMDIDNOTREPORTPATIENTSCHARACTERISTICSSUCHASLIVER FUNCTIONEVALUATION CONlRMATIONOFVIRALETIOLOGYTHROUGH0#2 (#6 VIRALGENOTYPEANDQUANTIlCATION ANDLIVERHISTOLOGY THUSPRECLUDING ABETTERINTERPRETATIONOFTHEIRRESULTS )NTHEONLYSTUDYFOUNDINLITERATUREWITHAMETHODOLOGICALDESIGN SIMILAR TO OURS 7)%$-!.. ET AL EVALUATED THE RESPONSE TO RECOMBINANT$.!VACCINEAGAINST("62ECOMBIVAX INADOSEOF G )- ATMONTHS ANDINPATIENTSWITHCHRONICHEPATITIS BY(#6VIRUSANDINHEALTHYVOLUNTEERS!MONGTHESEPATIENTS30 WASFOUNDIN 3#IN AND.2IN ANDINVOLUNTEERSTHE RESULTSWERE AND RESPECTIVELY 3IMILARLY TO THE 'ERMAN STUDY WE DID NOT lND A STATISTICALLY SIGNIlCANTDIFFERENCEWHENTHEVACCINALRESPONSEWASEVALUATEDINRELATION TOTHEHISTOLOGICALlNDINGS)NOTHERWORDS WHENTHEPATIENTSWITH ADIAGNOSISOFCHRONICHEPATITISWERECOMPAREDTOTHEPATIENTSWHO HADALREADYDEVELOPEDCIRRHOSIS NODIFFERENCEWASFOUNDCONCERNING SEROCONVERSIONAFTERTHEVACCINE 4WOLARGEMULTICENTRICSTUDIESPUBLISHEDIN DEMONSTRATED THATGENOTYPEANDVIRALLOADSHOULDBETAKENINTOACCOUNTDURING TREATMENTFORCHRONICHEPATITISBY(#6"ETTERRESULTSWEREOBSERVED IN PATIENTS WITH GENOTYPE OTHER THAN AND TO A LESSER EXTENT IN THOSE WITH LOW VIRAL LOAD CUT OFF POINT OF MILLION COPIESM, )NANANALOGYTOTHERESULTSOFTHESESTUDIES WEEVALUATEDTHEROLE OFGENOTYPEDETERMINATIONANDVIRALLOADINTHERESPONSEOBSERVED AFTERVACCINATION )NCONCERNTOTHEGENOTYPE PATIENTSWITHGENOTYPESHOWEDAWORSE RESPONSETOVACCINEASCOMPAREDTOPATIENTSWITHGENOTYPESAND 3UCHDATAHAVENEVERBEENREPORTEDINLITERATURE)N7)%$-!..ET ALSTUDY THISANALYSISWASIMPAIREDBECAUSEOFPATIENTSWERE OFGENOTYPE3UCHRESULTSHAVEAPRACTICALUSEBECAUSETHEYAFFECTTHE COST EFFECTIVENESSOFVACCINATIONINTHISPOPULATIONOFPATIENTS4HUS IT COULD BE INFERRED THAT SPECIALLY PATIENTS WITH GENOTYPE SHOULD USE A DIFFERENT VACCINATION SCHEDULE WITH HIGHER DOSES IN ORDER TO OBTAINABETTERVACCINALRESPONSE!SREGARDSTHECOST EFFECTIVENESSOF VACCINATION ITISIMPORTANTTOCITETHEWORKDEVELOPEDBY3)$$)15)

Y±QR±MXOVHW

ETAL INWHICHTHEYSTRESSTHEIMPORTANCEOFPREVIOUSPERFORMANCE OFMARKERSFORHEPATITIS"VIRUSINORDERTOSCREENTHEPOPULATIONTOBE BENElTEDBYVACCINATION #ONCERNINGVIRALLOAD ITSHOULDBESTRESSEDTHATTHEDISCRIMINATIVE CRITICALLEVELUSEDHEREWASBASEDONTHEFACTTHAT THOUGHTHETECHNIQUE OFBRANCHED $.!BEARSRESEMBLANCETOTHE0#2TECHNIQUEUSEDINTHE ABOVE MENTIONEDSTUDIES ALOGARITHMICCORRELATIONMUSTBEPERFORMED BETWEENTHERESULTS )NDOINGSO WEHAVEOBTAINEDTHECUT OFFLEVEL USEDINTHISSTUDY7HENTHEROLEOFVIRALLOADINTHERESPONSETOVACCINE WASEVALUATEDINPATIENTSWITHCHRONICLIVERDISEASE NODIFFERENCEWAS OBSERVEDBETWEENVALUESBELOWANDABOVECRITICALLEVELSOFQUANTIlCATION 4HESERESULTSARESIMILARTOTHOSEREPORTEDBY7)%$-!..ETAL "ECAUSE A DECREASED RESPONSE TO VACCINE IS RELATED TO AGE GENDER SMOKING AND OBESITY WE ATTEMPTED TO EVALUATE THE INmUENCE OF THESE PREDICTIVE FACTORS IN PATIENTS WITH CHRONIC LIVER DISEASE(OWEVER SIMILARLYTO7)%$-!..ETAL WEDIDNOTlND ASTATISTICALLYSIGNIlCANTDIFFERENCEAMONGRESPONDERSASCOMPARED TONON RESPONDERS)TISIMPORTANTTOSTRESSTHAT ALTHOUGHTHEREWASA STATISTICALLYSIGNIlCANTDIFFERENCEINTHEAGEOFPATIENTSWITHCHRONIC LIVERDISEASEASCOMPAREDTOTHATOFHEALTHYVOLUNTEERS THELOGISTIC REGRESSIONPERFORMEDTOASSESSTHEROLEOFAGEASACONFUSINGFACTOR IN THE COMPARISON OF RESPONSE TO VACCINE BETWEEN PATIENTS AND VOLUNTEERSREVEALEDTHATAGEWASUNRELATEDTORESPONSEWHENITWAS CONTROLLEDFORTHEFACTTHATTHEPATIENTWASEITHERACARRIERORNOTOF (#60OSSIBLYTHESEFACTORSOFWEAKRESPONSEWERENOTSIGNIlCANT HEREBECAUSETHEYWEREANALYZEDINANIMMUNOSUPPRESSEDPOPULATION 4HUS LIVERDISEASEWOULDBETHEPRIMARYFACTORINNON RESPONSEAND THEOTHERFACTORSWOULDNOTGREATLYAFFECTTHERESPONSETOVACCINE4HE SAMEWASFOUNDWHEN2/3-!.ETAL STUDIEDANOTHERPOPULATION OF IMMUNOSUPPRESSED INDIVIDUALS IN WHICH AGE AND "-) HAD NO SIGNIlCANTEFFECTONSEROCONVERSION /NLYFOUROFALLINDIVIDUALSINCLUDEDINTHISSTUDYREPORTEDLIGHT PAININTHEINJECTIONREGIONFOLLOWINGTHElRSTDOSEOFVACCINE WITHA DURATIONOFUPTO HOURS.OALTERATIONINAMINOTRANSFERASEACTIVITY WASOBSERVEDAFTERVACCINATION4HUSWECANCONCLUDE ASSHOWNIN LITERATURE THATANTI HEPATITIS"VACCINEISSAFEANDDOESNOT INTERFEREWITHTHECOURSEOFCHRONICHEPATITISBY(#6 7ECONCLUDETHATSEROCONVERSIONAFTERVACCINATIONAGAINST("6IS LOWINPATIENTSWITHCHRONICLIVERDISEASEBY(#64HUSWERECOMMEND THATTHISPOPULATIONOFPATIENTS PARTICULARLYTHOSEWITHGENOTYPE SHOULD BESUBMITTEDTOASCHEDULEWITHADOUBLEDOSEOFVACCINE SIMILARTO THEONEUSEDINPATIENTSUNDERHEMODIALYSIS !#+./7,%$'%-%.43 4HEAUTHORSWISHTOTHANK$R'UADALUPE'ARCIA 4SAOFORTHEHELPFUL COMMENTSANDSUGGESTIONS

$UT*DVWURHQWHURO


-ATTOS!! 'OMES%" 4OVO#6 !LEXANDRE#/0 2EMIÍO*/2%lCÈCIADAVACINAANTI HEPATITE"EMPACIENTESCOMDOENÎAHEPÈTICACRÙNICAPELOVÓRUSDA HEPATITE#!RQ'ASTROENTEROL 2ESUMO 2ACIONAL #ONSIDERANDOAIMUNOSSUPRESSÍODOSPACIENTESCOMDOENÎAHEPÈTICACRÙNICA SUARESPOSTAËVACINAÎÍOÏDISCUTIDANALITERATURA/BJETIVOS

!VALIARARESPOSTAËVACINAANTI HEPATITE"EMPACIENTESCOMHEPATITECRÙNICAPELOVÓRUS#-ÏTODOS %STUDOPROSPECTIVOAVALIANDOPACIENTESCOMINFECÎÍO PELOVÓRUS# ANOS HOMENS EADULTOSSAUDÈVEIS ANOS HOMENS #ARGAVIRALFOIDETERMINADAATRAVÏSDOB $.!EM PACIENTESEOGENØTIPOFOIDETERMINADOPORSEQàENCIAMENTOEMPACIENTES4ODOSOSPACIENTESEOSADULTOSSAUDÈVEISRECEBERAMTRÐSDOSESDAVACINA%NGERIX "¤)-AOS EDIAS 2ESPOSTASOROLØGICAËVACINAFOIDIVIDIDAEMTRÐSCATEGORIASSOROPROTEÎÍO QUANDOANTI ("SERArM5)M,SOROCONVERSÍO QUANDOANTI ("SERA M5)M,ENÍO REAGENTE QUANDOANTI ("SERAM5)M,2ESULTADOS !RESPOSTADAVACINAANTI HEPATITE"EMMÐSAPØS ADOSEFOISOROPROTEÎÍOEM SOROCONVERSÍOEM ENÍO REAGENTEEM ENTREOSPACIENTES E E RESPECTIVAMENTEEM ADULTOSSAUDÈVEIS/NÞMERODERESPOSTASNÍO REAGENTESFOISIGNIlCATIVAMENTEMAIOREMPACIENTESCOMDOENÎAHEPÈTICACRÙNICA3ESSENTAECINCOPACIENTES COMHEPATITECRÙNICAFORAMCOMPARADOSACIRRØTICOSCOMPENSADOSEMRELAÎÍOËRESPOSTAËVACINA MASNENHUMADIFERENÎAFOIOBSERVADA!RESPOSTAË VACINANOSPACIENTESCOMGENØTIPOSOUN FOIMELHORDOQUENAQUELESCOMGENØTIPON !RESPOSTANÍOFOIRELACIONADACOMACONCENTRAÎÍO DE6(# 2.!#ONCLUSÍO /NÞMERODENÍO RESPONDEDORESFOIMAIOREMPACIENTESCOMINFECÎÍOCRÙNICAPELOVÓRUS# INDEPENDENTEMENTEDOhSTATUSv HISTOLØGICOEDACARGAVIRAL²SUGERIDOQUETAISPACIENTESDEVERIAMRECEBERUMADOSEDUPLADEVACINA PARTICULARMENTEAQUELESCOMGENØTIPO $%3#2)4/2%3 6ACINASCONTRAHEPATITE"(EPATOPATIAS(EPACIVIRUS

2%&%2%.#%3

!VERHOFF& -AHONEY& #OLEMAN0 3CJATZ' (URWITZ% -ARGOCIS()MMUNOGENICITY OFHEPATITIS"VACCINES IMPLICATIONSFORPERSONALATOCCUPACIONALRISKOFHEPATITIS" VIRUSINFECTION!M*0REV-ED !WOFESO. ,EVY- (ARPER3 *ONES- (AYES- $OUGLAS* &ISHER- &OLPP$ 2ESPONSETO("6VACCINEINRELATIONTOVACCINEDOSEANDANTI (#6POSITIVITYANEW 3OUTH7ALESCORRECTIONALFACILITIES6ACCINE "EDOSSA0 0OYNARD4!NALGORITHMFORTHEGRADINGOFACTIVITYINCHRONIC#(EPATOLOGY "ENNET2' 0OWERS$# 2EMSBURG2% 3CHEVE! #LEMENTS-,(EPATITIS"VIRUS VACCINATIONFOROLDERADULTS*!M'ERIATR3OC "ERNER* +ADIAN- 0OST* -ULLER# 3CHWARTZ- #ONN- "ORCICH!0ROPHYLACTIC RECOMBINANTHEPATITIS"VACCINEINPATIENTSUNDERGOINGORTHOTOPICLIVERTRANSPLANTATION 4RANSPLANT0ROC "OSCH&8 2IBES* "ORRËS*%PIDEMIOLOGYOFPRIMARYLIVERCANCER3EMIN,IVER$IS #ENTERS FOR $ISEASE #ONTROL 2ECOMMENDATIONS OF THE!DVISORY #OMMITTEE ON 0REVENTIONOFHEPATITIS!THROUGHACTIVEORPASSIVE)MMUNIZATION0RACTICES!#)0 --72-ORB-ORTAL7KLY2EP #HALASANI . 3MALLWOOD ' (ALCOMB * &RIED -7 "OYER4$ )S VACCINATION AGAINSTHEPATITIS"INFECTIONINDICATEDINPATIENTSWAITINGFORORAFTERORTHOTOPICLIVER TRANSPLANTATION,IVER4RANSPL3URG #HIBA4 -ATSUZAKI9 !BEI-4HEROLEOFPREVIOUSHEPATITIS"VIRUSINFECTIONANDHEAVY SMOKINGINHEPATITIS#VIRUS RELATEDHEPATOCELLULARCARCINOMA!M*'ASTROENTEROL #LEMENS 3!# &ONSECA *# !ZEVEDO4 #AVALCANTI! 3ILVEIRA42 #ASTILHO -# #LEMENS23OROPREVALÐNCIAPARAHEPATITE!EHEPATITE"EMQUATROCENTROSDO"RASIL 2EV3OC"RAS-ED4ROP %!3, )NTERNATIONAL #ONSENSUS #ONFERENCE ON (EPATITIS # 0ARIS &EBRUARY #ONSENSUSSTATEMENT*(EPATOL %DDLESTON!-ODERNVACCINESnHEPATITIS,ANCET &ANG*73 !LBRECHT*+ *ACOBS3 ,AU*91UANTIlCATIONOFSERUMHEPATITIS#VIRUS 2.!(EPATOLOGY )LAN9 !SHUV9 4UR +ASPA2 3HOU5AL$#HRONICHEPATITIS#VIRUSINFECTIONWITH EXPOSURETOHEPATITIS"VIRUS)SR*-ED3CI +AMEL- %L-ANIALAWI- -ILLER&$2ECOMBINANTHEPATITIS"VACCINEIMMUNOGENICITY INPRESENCEOFHEPATITIS#VIRUSSEROPOSITIVITY,ANCETLETTER +ANE-!'LOBALSTATUSOSHEPATITIS"IMMUNIZATIONnCOMMENTARY,ANCET +ATKOV7. $IENSTAG*,0REVENTIONANDTHERAPYOFVIRALHEPATITIS3EMIN,IVER$IS +EEFFE%" )WARSON3 -CMAHON"* ,INDSAY+, +OFF23 -ANNS- "AUNCARTEN2 7IESE- &OURNEAU- 3AFARY! +LEMENS2 +RAUSE$33AFETYANDIMMUNOGENICITYOF HEPATITIS!VACCINEINPATIENTSWITHCHRONICLIVERDISEASE(EPATOLOGY ,EE 3$ #HAN #9 9U -) 7ANG9* #HANG &9 ,O +* 3AFARY! 3AFETY AND IMMUNOGENICITYOFINACTIVEDHEPATITIS!VACCINEINPATIENTSWITHCHRONICLIVERDISEASE *-ED6IROL ,EE3$ #HAN#9 9U-) ,U2( #HANG&9 ,O+*(EPATITIS"VACCINATIONINPATIENTS WITHCHRONICHEPATITIS#*-ED6IROL ,EMON3-!ND4HOMAS$,6ACCINESTOPREVENTVIRALHEPATITIS.%NGL*-ED ,OINAZ # *UANES *2 'ONZALES %- (EPATITIS " VACCINATION RESULTS IN LIVER TRANSPLANTRECIPIENTS(EPATOGASTROENTEROLOGY

-ARSANO,3 7EST$* #HAN) (ESLEY4- #OX* (ACKWORTH6 'REENBERG2.! TWO DOSEHEPATITIS"VACCINEREGIMENPROOFOFPRIMINGANDMEMORYRESPONSESIN YOUNGADULTS6ACCINE -ARTINOT 0EIGNOUX- "OYER. ,%"RETAN6 ,EGULUDEC' #ASTENAU# !KREMI 2 -ARCELLIN0!NEWSTEPTOWARDSTANDARDIZATIONOFSERUMHEPATITIS#VIRUS$.! QUANTIlCATIONINPATIENTSWITHCHRONICHEPATITIS#(EPATOLOGY -C(UTCHISON*' 'ORDON3# 3CHIFF%2 3HIFFMAN-, ,EE7- 2USTGI6+ 'OODMAN :$ ,ING-( #ORT3 !LBRECHT*+)NTERFERONALFAnBALONEORINCOMBINATIONWITH RIBAVIRINASINITIALTREATMENTFORCHRONICHEPATITIS#(EPATITIS)NTERVENTIONAL4HERAPY 'ROUP.%NGL*-ED .)(.ATIONAL)NSTITUTEOF(EALTHCONSENSUSDEVELOPMENTCONFERENCEPANELSTATEMENT MANAGEMENTOFHEPATITIS#(EPATOLOGYSUPPL 3 3 0OYNARD4 -ARCELLIN0 ,EE33 .IEDERAU# -INUCK'3 )DEO' "AIN6 (EATHCOTE * :EUZEM3 4REPO# !LBRECHT*2ANDOMIZEDTRIALOFINTERFERONªBPLUSRIBAVIRINFOR WEEKSORFORWEEKSVERSUSINTERFERONªBPLUSPLACEBOFORWEEKSFORTREATMENT OFCHRONICINFECTIONWITHHEPATITIS#VIRUS,ANCET 0UGH27( -URRAY ,YON)- $AWSON*,4RANSECTIONOFTHEOESOPHAGUSFORBLEEDING OESOPHAGEALVARICES"R*3URG 2OOME!* 7ALSH3* #ARTTER-, (ADLER*,(EPATITIS"VACCINERESPONSIVENESSIN #ONNECTICUTPUBLICSAFETYPERSONNEL*!-! 2OSMAN!3 "ASU0 'ALVIN+ ,IEBER#3%FlCACYOFAHIGHANDACCELERATEDDOSEOF HEPATITIS"VACCINEINALCOHOLICPATIENTSARANDOMIZEDCLINICALTRIAL!M*-ED 2OUDOT 4HRAVAL& "ASTIE! 0AWLOTSKY*- $HUMEAUX$%PIDEMIOLOGICALFACTORS AFFECTINGTHESEVERITYOFHEPATITIS#VIRUS RELATEDLIVERDISEASE!&RENCHSURVEYOF PATIENTS(EPATOLOGY 3AGNELLI % #OPPOLA . -ARROCCO #!CUTE HEPATITIS " IN (#6 CHRONIC CARRIERS VIROLOGICALINTERACTIONONCLINICALCOURSE(EPATOLOGY! 3IDDIQUI& -UTCHNICK- +INZIE* 0ELEMAN2 .AYLOR0 %HRINPREIS-0REVALENCE OFHEPATITIS!VIRUSANDHEPATITIS"VIRUSIMMUNITYINPATIENTSWITHPOLYMERASECHAIN REACTION CONlRMED(EPATITIS#IMPLICATIONSFORVACCINATIONSTRATEGY!M*'ASTROENTEROL 6AN4HIEL$( %L !SHMAWY, ,OVE+ 'AVALER*3 3TARZL4%2ESPONSETOHEPATITIS "VACCINATIONBYLIVERTRANSPLANTCANDIDATES$IG$IS3CI 6AN4HIEL$('AVALER*32ESPONSETO("6VACCINATIONINPATIENTSWITHSEVERE LIVERDISEASE!BSENSEOFAN(,!EFFECT$IG$IS3CI 6AN4HIEL$(6ACCINATIONOFPATIENTSWITHLIVERDISEASEWHO WHEN ANDHOW,IVER 4RANSPL3URG 6ENTO3 'AROFANO4 2ENZINI# #AINELLI& #ASALI& 'HIRONZI' &ERRARO4 #ONCIA% &ULMINANTHEPATITISASSOCIATEDWITHHEPATITIS!VIRUSSUPERINFECTIONINPATIENTSWITH CHRONICHEPATITIS#.%NGL*-ED 7IEDMANN- ,IEBERT5' /ESEN5 0ORST( 7IESE- 3CHROEDER3 (ALM5 -OSSNER * "ERR&$ECREASEDIMMUNOGENICITYOFRECOMBINANTHEPATITIS"VACINEINCHRONIC HEPATITIS#(EPATOLOGY 7ONG6 7REGHITT4' !LEXANDER'*0ROSPECTIVESTUDYOFHEPATITIS"VACCINATIONIN PATIENTSWITHCHRONICHEPATITIS#"-* 7OOD2# -ACDONALD+, 7HITE+% (EDBERG#7 (ANSON- /STERHOLM-42ISK FACTORSFORLACKOFDETECTABLEANTIBODYFOLLOWINGHEPATITIS"VACCINATIONOF-INNESOTA HEALTHCAREWORKERS*!-!

$UT*DVWURHQWHURO

2ECEBIDOEM !PROVADOEM

Y±QR±MXOVHW